Real-world effectiveness and safety of tralokinumab therapy in moderate-to-severe atopic dermatitis: insights from the TREATgermany registry

Research output: Contribution to journal › Letter › Contributed › peer-review

Contributors

  • Jan Hartmann - , University Hospital Schleswig-Holstein Campus Kiel (Author)
  • Inken Harder - , University Hospital Schleswig-Holstein Campus Kiel (Author)
  • Dora Stölzl - , University Hospital Schleswig-Holstein Campus Kiel (Author)
  • Melina Fonfara - , University Hospital Schleswig-Holstein Campus Kiel (Author)
  • Luise Heinrich - , Center for Evidence-Based Healthcare (Author)
  • Barbara Kind - , Center for Evidence-Based Healthcare (Author)
  • Jochen Schmitt - , Center for Evidence-Based Healthcare (Author)
  • Thomas Werfel - , Hannover Medical School (MHH) (Author)
  • Stephan Weidinger - , University Hospital Schleswig-Holstein Campus Kiel (Author)

Abstract

Real-world evidence from the TREATgermany registry demonstrated that tralokinumab has robust effectiveness and good tolerability and may provide improvements also in difficult-to-treat body areas.

Details

Original languageEnglish
Pages (from-to)494-497
Number of pages4
JournalClinical and Experimental Dermatology
Volume51
Issue number3
Publication statusPublished - Mar 2026
Peer-reviewedYes

External IDs

PubMed 41525295
ORCID /0009-0002-5254-6411/work/208795968

Keywords

ASJC Scopus subject areas